CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use
CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use
复制标题
DOI：
10.1111/j.1525-1438.2005.00130.x
复制
发表时间：
2005-09-01
影响因子：
4.8
通讯作者：
Zwirner, M
中科院分区：
文献类型：
--
作者：
Duffy, MJ;Bonfrer, JM;Zwirner, M
CA125是目前应用最广泛的卵巢上皮癌肿瘤标志物。本文旨在为卵巢癌患者CA125的常规临床应用提供指导。由于缺乏对I期疾病的敏感性和特异性，CA125在早期卵巢癌的检测中价值不大。因此，目前，CA125，无论是单独或与其他方式相结合，不能推荐用于筛查卵巢癌的无症状妇女的背景下，一个随机对照试验。然而，绝经后妇女术前水平可帮助鉴别盆腔肿块的良恶性。卵巢癌化疗期间的系列水平可用于评估对治疗的反应。虽然初始化疗后的系列监测可以早期发现复发性疾病，但这一提前时间的临床价值尚不清楚。CA125是卵巢癌标志物，应根据其判断这种恶性肿瘤的新标志物。
CA125 is currently the most widely used tumor marker for ovarian epithelial cancer. The aim of this article is to provide guidelines for the routine clinical use of CA125 in patients with ovarian cancer. Due to lack of sensitivity for stage I disease and lack of specificity, CA125 is of little value in the detection of early ovarian cancer. At present, therefore, CA125, either alone or in combination with other modalities, cannot be recommended for screening for ovarian cancer in asymptomatic women outside the context of a randomized controlled trial. Preoperative levels in postmenopausal women, however, may aid the differentiation of benign and malignant pelvic masses. Serial levels during chemotherapy for ovarian cancer are useful for assessing response to treatment. Although serial monitoring following initial chemotherapy can lead to the early detection of recurrent disease, the clinical value of this lead-time is unclear. CA125 is the ovarian cancer marker against which new markers for this malignancy should be judged.